Therapeutic actionsExact mechanisms

Therapeutic actions

Exact mechanisms of action not understood; main sites of action may be the limbic system and reticular formation; increases the effects of GABA, an inhibitory neurotransmitter; anxiety blocking effects occur at doses well below those necessary to cause sedation, ataxia.
Indications

Management of anxiety disorders, short-term relief of symptoms of anxiety; anxiety associated with depression.
Treatment of panic attacks with or without agoraphobia
Unlabeled uses: Social phobia, premenstrual syndrome, depression

Contraindications and cautions

Contraindicated with hypersensitivity to benzodiazepines, psychoses, acute narrow-angle glaucoma, shock, coma, acute alcoholic intoxication with depression of vital signs, pregnancy (crosses the placenta; risk of congenital malformations, neonatal withdrawal syndrome), labor and delivery (“floppy infant” syndrome), lactation (secreted in breast milk; infants become lethargic and lose weight).
Use cautiously with impaired liver or kidney function, debilitation.

Available forms

Tablets—0.25, 0.5, 1, 2 mg; XR tablets—0.5, 1, 2, 3 mg; oral solution—1 mg/mL; rapidly disintegrating tablets—0.25, 0.5, 1, 2 mg
Dosages

Individualize dosage; increase dosage gradually to avoid adverse effects.

ADULTS

Anxiety disorders: Initially, 0.25–0.5 mg PO tid; adjust to maximum daily dose of 4 mg/day in divided doses or extended-release form once per day in theAM once dosage is established (immediate release, intensol solution).
Panic disorder: Initially, 0.5 mg PO tid; increase dose at 3- to 4-day intervals in increments of no more than 1 mg/day; ranges of 1–10 mg/day have been needed; extended-release form once per day in AM once dosage is established (Xanax products, Niravam).

UNLABELED USES

Results (Indonesian) 1:

Therapeutic actionsExact mechanisms of action not understood; main sites of action may be the limbic system and reticular formation; increases the effects of GABA, an inhibitory neurotransmitter; anxiety blocking effects occur at doses well below those necessary to cause sedation, ataxia.Indications Management of anxiety disorders, short-term relief of symptoms of anxiety; anxiety associated with depression. Treatment of panic attacks with or without agoraphobia Unlabeled uses: Social phobia, premenstrual syndrome, depressionContraindications and cautions Contraindicated with hypersensitivity to benzodiazepines, psychoses, acute narrow-angle glaucoma, shock, coma, acute alcoholic intoxication with depression of vital signs, pregnancy (crosses the placenta; risk of congenital malformations, neonatal withdrawal syndrome), labor and delivery (“floppy infant” syndrome), lactation (secreted in breast milk; infants become lethargic and lose weight). Use cautiously with impaired liver or kidney function, debilitation.Available formsTablets—0.25, 0.5, 1, 2 mg; XR tablets—0.5, 1, 2, 3 mg; oral solution—1 mg/mL; rapidly disintegrating tablets—0.25, 0.5, 1, 2 mgDosagesIndividualize dosage; increase dosage gradually to avoid adverse effects.ADULTS Anxiety disorders: Initially, 0.25–0.5 mg PO tid; adjust to maximum daily dose of 4 mg/day in divided doses or extended-release form once per day in theAM once dosage is established (immediate release, intensol solution). Gangguan panik: awalnya, 0,5 mg PO tid; meningkatkan dosis interval 3 - 4-hari secara bertahap tidak lebih dari 1 mg/hari; kisaran 1-10 mg/hari diperlukan; diperpanjang-rilis form sekali sehari di AM setelah dosis didirikan (Xanax produk, Niravam).MENGGUNAKAN UNLABELED